Wells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price target decreased by analysts at Wells Fargo & Company from $28.00 to $26.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 134.66% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Scotiabank lowered their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday, January 16th. Jefferies Financial Group began coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Piper Sandler lowered their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Finally, William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Stock Performance

Shares of KROS opened at $11.08 on Thursday. The firm has a market cap of $448.82 million, a P/E ratio of -2.13 and a beta of 1.39. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The firm’s 50 day moving average price is $12.52 and its two-hundred day moving average price is $39.56.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Keros Therapeutics by 14.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after buying an additional 32,492 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at approximately $388,000. Barclays PLC grew its position in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after buying an additional 35,022 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Keros Therapeutics during the 3rd quarter worth $603,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.